ClinicalTrials.Veeva

Menu

Non-invasive Characterization of Systemic Microvascular Reactivity by Near-infrared Diffuse Optical Spectroscopy in COVID-19 Patients (HEMOCOVID19)

C

Corporacion Parc Tauli

Status

Enrolling

Conditions

Endothelial Function
COVID-19

Treatments

Device: Vascular occlusion test

Study type

Observational

Funder types

Other

Identifiers

NCT04689477
2020/579

Details and patient eligibility

About

The purpose of this study is to characterize microvascular reactivity on the forearm muscle using non-invasive near-infrared spectroscopy in critically ill COVID-19 patients, and to correlate its alterations with 28-day mortality in ICU COVID-19 patients.

Full description

After giving consent to participate in the study, the subjects included in the study will undergo a 15-minute measurement of tissue oxygen saturation (StO2) measured non-invasively on the forearm by means of near-infrared spectroscopy (NIRS). Once a baseline stable StO2 value is obtained, a provocative test, consisting of a transient vascular occlusion, will be performed. The test will allow the obtention of a local metabolic rate, and a StO2 recovery rate after the ischemic stimulus. This StO2 recovery rate will be considered as a reflection of the endothelial health of the patient.

Patients will be studied as soon as possible after admission to the ICU, and followed-up until ICU discharge or death.

Enrollment

612 estimated patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Recent diagnosis of SARS-CoV2 infection
  • Arterial hypoxemia and bilateral alveolar infiltrates, not explained by cardiac dysfunction or fluid overload.

Exclusion criteria

  • Severe peripheral vasculopathy
  • Raynaud's syndrome
  • Skin lesions or trauma in upper limbs interfering the placement of NIRS probe and/or the occlusion tourniquet
  • Deep venous thrombosis in the upper limbs

Trial design

612 participants in 3 patient groups

COVID-19
Description:
Hospitalized patients diagnosed with COVID-19, presenting with arterial hypoxemia.
Treatment:
Device: Vascular occlusion test
Control
Description:
Healthy subjects
Treatment:
Device: Vascular occlusion test
Non-COVID critically ill patients
Description:
Non-COVID critically ill patients admitted to the ICU.
Treatment:
Device: Vascular occlusion test

Trial contacts and locations

8

Loading...

Central trial contact

Jaume Mesquida, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems